The self-absorption effect is one of the main bottlenecks for the laser-induced breakdown spectroscopy (LIBS) technique. In this Letter, LIBS assisted by laser-stimulated absorption (LSA-LIBS) is proposed to solve this problem. The process of LSA in self-absorption reduction is discussed and confirmed. The serious self-absorption phenomena of spectral lines (K, Mn, and Al) were not observed in LSA-LIBS. The full width at half-maximum (FWHM) of K, Mn, and Al was reduced by about 58%, 25%, and 52%, respectively. The results demonstrate the capability of this approach to self-absorption reduction in the LIBS technique.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1364/OL.40.005224 | DOI Listing |
Dokl Biochem Biophys
January 2025
Bakulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russia.
The study presents a numerical parametric investigation of flow structures in channels with a longitudinal-radial profile zR = Const and a spherical dome at the base. The goal of the study was to examine the flow structures in these channels depending on the exponent N of the profile and the height of the dome, to determine the conditions that provide optimal centripetal swirling flow, analogous to blood flow in the heart chambers and major vessels. The investigation was conducted using a comparative analysis of flow structures in channel configurations zR = Const, carried out in two stages.
View Article and Find Full Text PDFDermatol Ther (Heidelb)
January 2025
Department of Clinical and Molecular Sciences-Dermatological Clinic, Università Politecnica Delle Marche, Ancona, Italy.
Introduction: Palmoplantar psoriasis (PPp) has a profound negative impact on patients' quality of life, and it represents a therapeutic challenge, as palms and soles are difficult to treat area. Although the efficacy profile of tildrakizumab has been well evaluated in the literature, data on its use for PPp are still limited. The objective of the study was to evaluate the efficacy and safety of tildrakizumab on moderate-to-severe plaque psoriasis with involvement of the palmoplantar area.
View Article and Find Full Text PDFPaediatr Drugs
January 2025
Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
Despite significant global reductions in cases of pneumonia during the last 3 decades, pneumonia remains the leading cause of post-neonatal mortality in children aged <5 years. Beyond the immediate disease burden it imposes, pneumonia contributes to long-term morbidity, including lung function deficits and bronchiectasis. Viruses are the most common cause of childhood pneumonia, but bacteria also play a crucial role.
View Article and Find Full Text PDFRice (N Y)
January 2025
Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi, 464-8601, Japan.
Enhancing nitrogen (N) fixation in rice plants can reduce N fertilizer application and contribute to sustainable rice production, particularly under low-N conditions. However, detailed microbial and metabolic characterization of N fixation in rice stems, unlike in the well-studied roots, has not been investigated. Therefore, the aim of this study was to determine the active N-fixing sites, their diazotroph communities, and the usability of possible carbon sources in stems compared with roots.
View Article and Find Full Text PDFAm J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Oral bempedoic acid (NEXLETOL in the USA; Nilemdo in the EU) and the fixed dose combination (FDC) of bempedoic acid/ezetimibe (NEXLIZET in the USA; Nustendi in the EU) are approved to reduce cardiovascular (CV) risk in statin-intolerant patients who are at high risk for, or have, CV disease. A first-in-class therapy, bempedoic acid inhibits the adenosine triphosphate-citrate lyase enzyme in the cholesterol biosynthesis pathway. In the multinational phase III CLEAR Outcomes trial in statin-intolerant patients, once-daily bempedoic acid 180 mg significantly reduced the risk of the primary endpoint (a four-component major adverse CV event composite of CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization) compared with placebo.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!